Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects

被引：0
|
作者：
Henderson, A.
Allen, A.
Gupta, A.
Renaux, J.
Brealey, N.
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2014年 / 44卷
关键词：
Bronchodilators; COPD; -; management; Pharmacology;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P938
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [32] CONSISTENCY OF DOSE DELIVERY OF FLUTICASONE FUROATE (FF)/UMECLIDINIUM (UMEC)/VILANTEROL (VI) ACROSS PATIENT RELEVANT INHALATION FLOW RATES FROM A DRY-POWDER INHALER (DPI)
    Prime, David
    Hamilton, Melanie
    Patmore, Oonagh
    CHEST, 2019, 156 (04) : 1786A - 1786A
  • [33] Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [34] Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial
    Zheng, Jinping
    Zhong, Nanshan
    Wang, Changzheng
    Wei, Li Ping
    Zhou, Xiang Dong
    Zhao, Li
    Dong Yuan, Ya
    He, Bei
    Wu, Bin
    Du, Xin
    Song, Jie
    Lipson, David A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 145 - 155
  • [35] The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
    Halpin, D. M. G.
    Bardsley, S.
    Criner, G.
    Dransfield, M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    Lange, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [36] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [37] The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment
    Allen, Ann
    Hardes, Kelly
    Kempsford, Rodger
    Tombs, Lee
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [38] Network Meta-analysis (NMA) of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Compared with other Triple Therapies for the Treatment of chronic obstructive Pulmonary Disease (COPD): A Comparison of annualized Rates of moderate and severe Exacerbations
    Ismaila, A.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenaes, M.
    Risebrough, N.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C.
    Halpin, D.
    PNEUMOLOGIE, 2023, 77 : S96 - S96
  • [39] In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles
    Prime, D.
    Hamilton, M.
    Taylor, E.
    PNEUMOLOGIE, 2020, 74 : S44 - S45
  • [40] The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with severe renal impairment
    Allen, Ann
    Hardes, Kelly
    Kempsford, Rodger
    Tombs, Lee
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345